Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2,248 | $1,828 | $1,037 | $844 |
| % Growth | 23% | 76.2% | 22.9% | – |
| Cost of Goods Sold | $323 | $310 | $169 | $140 |
| Gross Profit | $1,925 | $1,518 | $869 | $704 |
| % Margin | 85.6% | 83% | 83.7% | 83.4% |
| R&D Expenses | $1,126 | $1,004 | $883 | $792 |
| G&A Expenses | $976 | $796 | $771 | $621 |
| SG&A Expenses | $976 | $796 | $771 | $621 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$2 |
| Operating Expenses | $2,102 | $1,800 | $1,654 | $1,413 |
| Operating Income | -$177 | -$282 | -$785 | -$709 |
| % Margin | -7.9% | -15.4% | -75.7% | -83.9% |
| Other Income/Exp. Net | -$200 | -$151 | -$342 | -$143 |
| Pre-Tax Income | -$377 | -$434 | -$1,127 | -$852 |
| Tax Expense | -$99 | $7 | $4 | $1 |
| Net Income | -$278 | -$440 | -$1,131 | -$853 |
| % Margin | -12.4% | -24.1% | -109% | -101% |
| EPS | -2.18 | -3.52 | -9.3 | -7.2 |
| % Growth | 38.1% | 62.2% | -29.2% | – |
| EPS Diluted | -2.18 | -3.52 | -9.3 | -7.2 |
| Weighted Avg Shares Out | 128 | 125 | 122 | 118 |
| Weighted Avg Shares Out Dil | 128 | 125 | 122 | 118 |
| Supplemental Information | – | – | – | – |
| Interest Income | $122 | $96 | $25 | $2 |
| Interest Expense | $142 | $121 | $156 | $143 |
| Depreciation & Amortization | $57 | $54 | $44 | $48 |
| EBITDA | -$179 | -$258 | -$927 | -$662 |
| % Margin | -8% | -14.1% | -89.3% | -78.4% |